The Latest Cardiac and Vascular News
ABBOTT PARK, Ill., Sept. 22, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for one of Abbott’s most widely-used implantable cardioverter defibrillators (ICD) and associated high voltage leads. The approval of MR-conditional labeling for the Ellipse ICD with the Tendril MRI […]
Time to throw in the towel for Abbott on this generation of their Absorb BVS because of slow sales. However, there could still be a platform for this technology… Abbott halts global sales of 1st-gen Absorb stents SEPTEMBER 8, 2017 BY FINK DENSFORD , MassDevice Abbott (NYSE:ABT) said today it will halt global sales […]
ABBOTT PARK, Ill., Aug. 29, 2017 – Today, Abbott notified physicians of updates to its implantable pacemakers and defibrillators as part of its ongoing commitment to continuously improve patient care. The new device updates include a Battery Performance Alert for our implantable cardioverter defibrillators (ICDs) that provides physicians with earlier […]
ABBOTT PARK, Ill., Aug. 28, 2017 /PRNewswire/ — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left Ventricular Assist System (also known as an LVAD). The HeartMate 3 system provides a new option for physicians managing advanced heart failure patients in need […]
ABBOTT PARK, Ill., June 9, 2017 /PRNewswire/ — The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 26.5 cents per share. This marks the 374th consecutive quarterly dividend to be paid by Abbott since 1924. The cash dividend is payable Aug. 15, 2017, to […]
ABBOTT PARK, Ill., May 8, 2017 /PRNewswire/ — Abbott (NYSE: ABT) today announced CE Mark and first use of the new Confirm Rx Insertable Cardiac Monitor (ICM), the world’s first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, including atrial fibrillation (AF), to help guide therapy. […]
By Ken Dropkiewski The bioresorbable stent was approved for use by the FDA in July of 2016. The Absorb GT1 Bioresorbable Vascular Scaffold System, manufactured by Abbott, was all set to solve a litany of the problems inherent with conventional cardiac and vascular stents. Conventional stents, made of flexible metal […]
WASHINGTON, March 18, 2017 /PRNewswire/ — Abbott (ABT) today announced favorable one-year outcomes from the largest study of real-world experience for the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the United States. MitraClip treats people with degenerative mitral regurgitation (DMR, also known as leaky heart valve), a […]
